Moderna's 2025 Revenue Outlook Reduced Amid Shipment Delays and Earnings Watch
TL;DR Summary
Moderna lowered its 2025 revenue forecast due to a delay in vaccine shipments to the UK but exceeded Wall Street expectations for Q2, posting a smaller loss and higher revenue driven mainly by Covid vaccine sales, while also implementing cost cuts and workforce reductions.
- Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K. CNBC
- Moderna Logs Sales Beat Despite Declining Vaccine Demand The Wall Street Journal
- Moderna’s Loss Narrows After Cost-Cutting Efforts Take Hold (MRNA) Bloomberg
- Moderna to Report Earnings as Cash Balance Shrinks Barron's
- Moderna Earnings: What To Look For From MRNA Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
90%
450 → 44 words
Want the full story? Read the original article
Read on CNBC